Akari Therapeutics (AKTX) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Akari Therapeutics (AKTX) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Akari Therapeutics

· AKTX

Dashboard

Financials

Ratios

Valuation

Statistics

17.051 M

+0.22%

General

Market Cap: $17.01M
Enterprise Value: $3.93M
Shares Outstanding: 3,569,610,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: —
Operating Margin: —
Net Profit Margin: —
FCF Margin: —
ROA: -80.16%
ROE: -147.45%
ROIC: -115.17%
Current Ratio: 0.60
Debt-to-Equity: 0.04
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: -0.05
P/S: —
P/FCF: —
P/B: 0.59
EV/EBITDA: -0.12

Growth

Rev 1Y: —
Rev 1Y Fwd Est: —
Rev 3Y (CAGR): —
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR): —
EPS 10Y (CAGR): —

Income Statement (TTM)

Revenue: —
Gross Margin: —
Operating Expenses: $30.99M
Operating Income: -$30.99M
Net Profit: -$30.96M

Balance Sheet

Cash and Equivalents: $7.69M
Working Capital: -$5.61M
Total Assets: $38.62M
Net Debt: -$7M
Total Liabilities: $20.03M
Total Equity: $18.6M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$10.74M
Cash Flow from Investing: -$15K
Cash Flow from Financing: $15.72M
Free Cash Flow: -$10.74M
Capital Expenditures: $2